Institution
Centenary Institute
About: Centenary Institute is a based out in . It is known for research contribution in the topics: Immune system & Hypertrophic cardiomyopathy. The organization has 434 authors who have published 678 publications receiving 25097 citations. The organization is also known as: Centenary Institute of Cancer Medicine and Cell Biology & Centenary.
Papers published on a yearly basis
Papers
More filters
••
Daniel J. Klionsky1, Amal Kamal Abdel-Aziz2, Sara Abdelfatah3, Mahmoud Abdellatif4 +2980 more•Institutions (777)
TL;DR: In this article, the authors present a set of guidelines for investigators to select and interpret methods to examine autophagy and related processes, and for reviewers to provide realistic and reasonable critiques of reports that are focused on these processes.
Abstract: In 2008, we published the first set of guidelines for standardizing research in autophagy. Since then, this topic has received increasing attention, and many scientists have entered the field. Our knowledge base and relevant new technologies have also been expanding. Thus, it is important to formulate on a regular basis updated guidelines for monitoring autophagy in different organisms. Despite numerous reviews, there continues to be confusion regarding acceptable methods to evaluate autophagy, especially in multicellular eukaryotes. Here, we present a set of guidelines for investigators to select and interpret methods to examine autophagy and related processes, and for reviewers to provide realistic and reasonable critiques of reports that are focused on these processes. These guidelines are not meant to be a dogmatic set of rules, because the appropriateness of any assay largely depends on the question being asked and the system being used. Moreover, no individual assay is perfect for every situation, calling for the use of multiple techniques to properly monitor autophagy in each experimental setting. Finally, several core components of the autophagy machinery have been implicated in distinct autophagic processes (canonical and noncanonical autophagy), implying that genetic approaches to block autophagy should rely on targeting two or more autophagy-related genes that ideally participate in distinct steps of the pathway. Along similar lines, because multiple proteins involved in autophagy also regulate other cellular pathways including apoptosis, not all of them can be used as a specific marker for bona fide autophagic responses. Here, we critically discuss current methods of assessing autophagy and the information they can, or cannot, provide. Our ultimate goal is to encourage intellectual and technical innovation in the field.
1,129 citations
••
University of Paris-Sud1, Institut Gustave Roussy2, University of California, San Francisco3, Harvard University4, University of Texas MD Anderson Cancer Center5, Memorial Sloan Kettering Cancer Center6, Centenary Institute7, University of Sydney8, Mayo Clinic9, University of Pennsylvania10, University of Pittsburgh11, Merck & Co.12, University of California, Los Angeles13
TL;DR: This 5-year analysis of KEYNOTE-001 represents the longest follow-up for pembrolizumab to date and confirms the durable antitumor activity and tolerability of pembrolezumab in advanced melanoma.
560 citations
••
TL;DR: Transgene‐derived factor IX coagulant activity enabled the termination of baseline prophylaxis and the near elimination of bleeding and factor use in 10 participants with hemophilia who received the same vectors.
Abstract: BackgroundThe prevention of bleeding with adequately sustained levels of clotting factor, after a single therapeutic intervention and without the need for further medical intervention, represents an important goal in the treatment of hemophilia. MethodsWe infused a single-stranded adeno-associated viral (AAV) vector consisting of a bioengineered capsid, liver-specific promoter and factor IX Padua (factor IX–R338L) transgene at a dose of 5×1011 vector genomes per kilogram of body weight in 10 men with hemophilia B who had factor IX coagulant activity of 2% or less of the normal value. Laboratory values, bleeding frequency, and consumption of factor IX concentrate were prospectively evaluated after vector infusion and were compared with baseline values. ResultsNo serious adverse events occurred during or after vector infusion. Vector-derived factor IX coagulant activity was sustained in all the participants, with a mean (±SD) steady-state factor IX coagulant activity of 33.7±18.5% (range, 14 to 81). On cumu...
491 citations
••
TL;DR: CD8+ T-cell behaviour is similar to Lévy strategies reported in organisms ranging from mussels to marine predators and monkeys, and CXCL10 aids T cells in shortening the average time taken to find rare targets.
Abstract: Chemokines have a central role in regulating processes essential to the immune function of T cells, such as their migration within lymphoid tissues and targeting of pathogens in sites of inflammation. Here we track T cells using multi-photon microscopy to demonstrate that the chemokine CXCL10 enhances the ability of CD8+ T cells to control the pathogen Toxoplasma gondii in the brains of chronically infected mice. This chemokine boosts T-cell function in two different ways: it maintains the effector T-cell population in the brain and speeds up the average migration speed without changing the nature of the walk statistics. Notably, these statistics are not Brownian; rather, CD8+ T-cell motility in the brain is well described by a generalized Levy walk. According to our model, this unexpected feature enables T cells to find rare targets with more than an order of magnitude more efficiency than Brownian random walkers. Thus, CD8+ T-cell behaviour is similar to Levy strategies reported in organisms ranging from mussels to marine predators and monkeys, and CXCL10 aids T cells in shortening the average time taken to find rare targets.
483 citations
••
Northwestern University1, Lucile Packard Children's Hospital2, University of Pennsylvania3, Centenary Institute4, University of Sydney5, Royal Prince Alfred Hospital6, University of Paris7, Mahidol University8, University of California, Los Angeles9, Université Paris-Saclay10, Paris Descartes University11, Pierre-and-Marie-Curie University12, German Cancer Research Center13, Children's Hospital Oakland Research Institute14, Harvard University15
TL;DR: Gene therapy with autologous CD34+ cells transduced with the BB305 vector reduced or eliminated the need for long‐term red‐cell transfusions in 22 patients with severe β‐thalassemia without serious adverse events related to the drug product.
Abstract: Background Donor availability and transplantation-related risks limit the broad use of allogeneic hematopoietic-cell transplantation in patients with transfusion-dependent β-thalassemia. After previously establishing that lentiviral transfer of a marked β-globin (βA-T87Q) gene could substitute for long-term red-cell transfusions in a patient with β-thalassemia, we wanted to evaluate the safety and efficacy of such gene therapy in patients with transfusion-dependent β-thalassemia. Methods In two phase 1–2 studies, we obtained mobilized autologous CD34+ cells from 22 patients (12 to 35 years of age) with transfusion-dependent β-thalassemia and transduced the cells ex vivo with LentiGlobin BB305 vector, which encodes adult hemoglobin (HbA) with a T87Q amino acid substitution (HbAT87Q). The cells were then reinfused after the patients had undergone myeloablative busulfan conditioning. We subsequently monitored adverse events, vector integration, and levels of replication-competent lentivirus. Efficac...
474 citations
Authors
Showing all 434 results
Name | H-index | Papers | Citations |
---|---|---|---|
Glenda M. Halliday | 111 | 676 | 53684 |
Peter Hersey | 90 | 399 | 37026 |
Stuart G. Tangye | 86 | 259 | 24706 |
John F. Allen | 79 | 401 | 23214 |
Geoffrey W. McCaughan | 75 | 524 | 21798 |
Wolfgang Weninger | 72 | 325 | 21882 |
Woon-Puay Koh | 67 | 394 | 17085 |
Adrian Smith | 65 | 256 | 12098 |
Jennifer R. Gamble | 64 | 140 | 15166 |
Philip M. Hansbro | 63 | 403 | 13862 |
Mathew A. Vadas | 63 | 164 | 16735 |
Warwick J. Britton | 62 | 327 | 13749 |
Antony Basten | 62 | 225 | 15493 |
John E.J. Rasko | 57 | 233 | 11524 |
Christopher Semsarian | 56 | 367 | 15292 |